Core Insights - Abbott showcased its lead product, the AVEIR series of leadless pacemakers, at the 8th China International Import Expo, highlighting its unique position as the world's first and only true dual-chamber leadless pacing system [1] - The AVEIR VR single-chamber leadless pacemaker was first exhibited in 2022 and has since been clinically applied in China, benefiting thousands of patients with bradycardia [1][2] - The market for cardiac pacemakers in China is growing at an annual rate of 10%-15%, with over 140,000 implantations recorded in 2023 [2] Company Developments - Abbott's AVEIR DR dual-chamber leadless pacemaker debuted at the 2023 expo and has been approved for clinical use across nearly 20 provinces and over 50 top medical centers in China [2] - The AVEIR series utilizes Abbott's proprietary i2i communication technology, allowing real-time information transfer between implanted devices to simulate normal heart contraction rhythms [2] - The introduction of these leadless pacemakers enables personalized and precise pacing treatment plans tailored to individual patient needs, enhancing patient care and management [2] Clinical Impact - The AVEIR series has shown significant clinical application in China, with the technology effectively improving survival rates and quality of life for patients ranging from 6 to 98 years old [1] - Abbott's leadless pacemakers are designed to reduce surgical time and enhance safety, allowing patients to return to normal life more quickly post-surgery [2] - The ability to adjust treatment plans based on patient conditions supports both current and future healthcare needs, maximizing patient benefits [2]